Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03602859
Title A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

ovarian clear cell adenocarcinoma

ovarian serous carcinoma

ovarian seromucinous carcinoma

ovarian endometrial cancer

ovarian carcinosarcoma

Therapies

Dostarlimab-gxly + Niraparib

Niraparib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.